MinervaX, a Copenhagen, Denmark-based biotechnology company, raised €72M in funding.
The €22M equity round was led by Trill Impact Ventures and Pureos Bioventures with participation from REPAIR Impact Fund, Sunstone Life Science Ventures, LF Investment, Wellington Partners, Sanofi Ventures, Adjuvant Capital and Industrifonden. In addition to the equity financing, the European Investment Bank provided a €50M loan facility. In conjunction with the financing, Bita Sehat, Senior Director at Trill Impact Ventures, and Veronica Gambillara, Partner of Pureos Bioventures, will join the Board of Directors.
The company intends to use the funds to advance the late-stage development of its GBS vaccine candidate in preparation for a Phase 3 clinical trial.
Led by CEO Per Fischer, MinervaX is a biotechnology company advancing a prophylactic vaccine against Group B Streptococcus (GBS), based on research from Lund University. The company is developing a GBS vaccine for maternal immunization, based on fusions of highly immunogenic and protective protein domains from selected surface proteins of GBS (the Alpha-like protein family).
FinSMEs
15/12/2022